Home
Companies
Catalysts
Deep Dives
Obeldesivir
obeldesivir (GS-5245)
PHASE2
Drug Profile
Modality
Small molecule
Route
PO
Therapy Area
Infectious Disease
Peak Sales Est
$1000M
Formulations
[]
Companies
GILD
(ORIGINATOR)
100%
Mechanism: Nucleoside analog antiviral
Expert:
Oral nucleoside analog prodrug metabolized to active triphosphate. Inhibits viral RNA-dependent RNA polymerase.
Everyday:
An oral antiviral that stops viruses from copying their genetic material.
Targets: []
Programs (1)
Indication
Stage
Key Study
Regional Status
Acute RSV infection
PHASE2
Phase 2 RSV
—
Data from Supabase · Updated 2026-03-24